

INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF
CHANDAN PHARMACY LIMITED
(CIN- U47721UP2017PLC193492)
Report on the audit of Financial Statements**

Opinion

We have audited the financial statements of CHANDAN PHARMACY LIMITED ('the Company'), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss and Statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021, ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, its **Profit** and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: -SEJ Plaza – Second Floor, Office No S34, Marve Road, Above N M Medical, Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.
Branch Office: - A-504, Ansal Chamber-1, Bhikaji Cama Place, New Delhi-110066.
☎ :CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in, navodit@msnt.in, manoj@msnt.in

Board's Report and Shareholder's Information but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management and those charged with governance for Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the AS and other accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditors Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable



assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our



audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with the Companies (Accounting Standards) Rules, 2021.
 - e) On the basis of the written representations received from the directors as on 31st March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
 - g) In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Company does not have any pending litigation which would impact its financial position.



- ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv) (a) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entity ("Intermediaries"), which the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- (d) The Company has neither declared nor paid any dividend during the year.
2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure B, a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 018542C/C400322

Navodit Tyagi
Partner

Membership No. - 533375
UDIN No: - 25533375BMOKNN3748
Place: Noida



Date: 27/05/2025

Annexure A to the Independent Auditors' Report
Report on the Internal Financial Controls under Clause (i) of sub-section 3 of
Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of Chandan Pharmacy Limited ("the Company") as of 31 March 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial



statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 018542C/C400322

Navodit Tyagi

Partner

Membership No.-533375

UDIN No:-25533375BMOKNN3748



Place: Noida
Date: 27/05/2025

Annexure B to the Independent Auditor's Report to the Shareholders

The Annexure referred to in our Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31 March 2025, we report that:

- i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:
 - (a) (A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipment.

(B) The Company has not intangible assets and hence this clause is not applicable.
 - (b) According to the Information and explanations given to us and on the basis of our examination of the record of the Company, the Property, Plant and Equipment's have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
 - (c) According to the information and explanations given to us and on the basis of our examination of the record of the Company, the company does not hold any immovable properties and therefore this clause of the order regarding title deed of the immovable property is not applicable.
 - (d) According to the information and explanation given to us and on the basis of our examination of the record of the Company, the Company has not revalued any of its Property, Plant & Equipment (including Right of Use assets) or intangible assets during the year. Accordingly, the reporting under clause 3(i)(d) of the order is not applicable to the company.
 - (e) According to the information and explanation given to us and on the basis of our examination of the record of the Company, no proceedings have been initiated during the year or are pending against the Company as at March 31, 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made there under.
- ii. (a) As explained to us and on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No material



discrepancies were noticed on physical verification of inventories by the management as compared to the book records.

- (b) During the year, the Company has been sanctioned working capital limits in excess of Rs. 5.00 crores, in aggregate, from banks on the basis of security of current assets. The Company has filed quarterly statements with such banks, which are in agreement with the books of account.
- iii. In our opinion and based on the information and explanation given to us and based on our examination of record of the Company, Company has not made investments in, provided any guarantee or security or granted any loans or advances, in nature of loans, secured or unsecured to companies, firms, Limited Liability Partnerships, or other parties. Accordingly, Paragraph 3(iii) of the order is not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us, the company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provision of section 185 of the Act and the Company has not made investments through more than two layers of the investment companies in accordance with the provision of section 186 of the Act. Accordingly, Reporting under clause 3(iv) of the Order is not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the Public during the year. Therefore, the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- vi. The Central Government of India has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Act for any of the activities of the company and accordingly paragraph 3 (vi) of the order is not applicable
- vii. a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, GST, cess and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities. As explained to us, the Company did not have any dues on account of employees' state insurance and duty of excise.



According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, cess, GST and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

b) According to the information and explanations given to us and the records of the company examined by us, there are no dues of income-tax, sales-tax, service tax, goods and service tax, duty of customs, duty of excise and value added tax which have not been deposited on account of any dispute.

- viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- ix. (a) Based on our audit procedures and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) According to information and explanation given to us and on the basis of our examination of the records of the Company, the company has not been declared a willful defaulter by any bank or financial institution or any lender.
- (c) Based on our audit procedures and according to the information and explanations given to us, the Company has utilized the term loans for the purpose for which loans were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on a short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) The company does not hold any investment in any subsidiary, associate, or joint venture (as defined under the act) during the year ended 31st March 2025. Accordingly, 3(ix)(e) and 3(ix)(f) is not applicable.
- x. (a) The Company has not raised money by way of Initial Public offer or further public offer (including debts instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the order is not applicable.
- xi. (a) To the best of our knowledge and belief and according to the information and explanations given to us, no fraud by the Company or any fraud on the company has been noticed or reported during the year.



(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form-ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to date of this report.

(c) According to the information and explanations given to us by management, no whistle-blower complaints have been received by the Company.

- xii. The Company is not a Nidhi company. Therefore, the provisions of clause 3(xii)(a), 3(xii)(b) and 3(ix)(c) of the Order are not applicable.
- xiii. In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details of such transactions have been disclosed in the notes to the financial statements as required by the applicable Accounting Standard.
- xiv. According to the information and explanations given to us and based on our verification, the provisions of Section 138 of the Companies Act, 2013 relating to internal audit are not applicable to the company. Accordingly, reporting under clause 3(xiv) of the Order is not applicable.
- xv. In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with its directors or persons connected with him and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3 (xvi) (a) of the Order is not applicable to the Company.
- (b) In our opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities during the year. Accordingly, clause 3 (xvi) (b) of the Order is not applicable to the Company.
- (c) In our opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulation made by the Reserve Bank of India. Accordingly, clause 3 (xvi) (c) of the Order is not applicable to the Company.
- (d) According to information and explanations given by the management, the group does not have any CIC as part of the Group.



- xvii. The company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. According to the information and explanations given to us, there has been no resignation of the statutory auditors during the year.

- xix. According to information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company.

We further state that our reporting is based on facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx. Based on our examination and according to the information and explanations given to us, the provisions of section 135 of the Companies Act are not applicable to the company. Accordingly, clause 3(xx)(a) and 3(xx)(b) of the order are not applicable.
- xxi. As the report is with respect of standalone financial statements, therefore, clause 3(xxi) of the order is not applicable.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner

Membership No.-533375
UDIN No: -25533375BMOKNN3748

Place: Noida
Date: 27/05/2025



Company name :- CHANDAN PHARMACY LIMITED

CIN :- U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Statement of Assets & Liabilities as at 31st March, 2025

Particulars	Note No.	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	32.30	32.30
(b) Reserves and surplus	4	772.11	481.70
(c) Money received against share warrants		-	-
(2) Share application money pending allotment		-	-
(3) Minority interest		-	-
(4) Non-current liabilities			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities(net)		-	-
(c) Other long-term liabilities		-	-
(d) Long term provisions	5	30.69	22.09
(5) Current liabilities			
(a) Short-term borrowings	6	1,496.00	683.27
(b) Trade payables	7		
(i) Total outstanding dues of micro & small enterprises.		346.32	481.07
(ii) Total outstanding dues of creditors other than micro & small enterprises.		1,157.19	856.11
(c) Other current liabilities	8	89.59	130.97
(d) Short term provisions	9	3.92	0.61
TOTAL		3,928.12	2,688.12
II. ASSETS			
(1) Non- current assets			
(a) Property, plant & equipments & intangible assets	10		
(i) Property, plant & equipments		42.05	51.85
(ii) Intangible assets		-	-
(iii) Capital work in progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments	11	114.75	114.75
(c) Deferred tax assets(net)	12	18.04	3.77
(d) Long -term loans and advances	13	0.11	0.11
(e) Other non-current assets	14	80.88	40.16
(2) Current assets			
(a) Current investments		-	-
(b) Inventories	15	1,425.08	1,178.56
(c) Trade receivables	16	1,495.00	675.34
(d) Cash and bank balances	17	15.66	316.55
(e) Short-term loans and advances	18	196.90	258.50
(f) Other current assets	19	539.65	48.53
TOTAL		3,928.12	2,688.12

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Firm registration no. :- 018542C/C400322

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNN3748

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors

CHANDAN PHARMACY LIMITED

Amar Singh

Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

Company name :- CHANDAN PHARMACY LIMITED

CIN :- U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Statement of Profit and loss for the year ended 31st March, 2025

Particulars	Note No.	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
I. Revenue from operations	20	10,124.83	7,611.60
II. Other income	21	87.70	13.36
III. Total revenue(I+II)		10,212.53	7,624.96
IV. Expenses:			
Cost of material consumed	22	16.73	16.07
Purchase of stock-in-trade	23	9,067.65	6,980.79
Change in inventories of finished goods, work-in-progress and stock-in-trade.	24	(263.14)	(227.25)
Employee benefits expense.	25	547.54	449.86
Finance Costs	26	99.75	63.80
Depreciation and amortisation expense	10	32.24	4.33
Other expenses	27	305.19	311.67
Total expenses (IV)		9,805.96	7,599.27
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)		406.57	25.69
VI. Exceptional items		-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)		406.57	25.69
VIII. Extraordinary items		-	-
IX. Profit/(loss) before tax (VII- VIII)		406.57	25.69
X. Tax expense of continuing operation:-			
Current tax	-	130.44	13.79
Deferred tax		(14.27)	(3.89)
Tax expense(X)		116.17	9.90
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)		290.40	15.79
XII. Profit/(loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)		-	-
XV. Share of (profit)/ loss transferred to minority interest		-	-
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)		290.40	15.79
XVII. Earnings per equity share:			
(1) Basic		89.91	4.89
(2) Diluted	28	89.91	4.89

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Firm registration no. :- 018542C/C400322

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNN3748

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors
CHANDAN PHARMACY LIMITED

Amar Singh

Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

Company name :- CHANDAN PHARMACY LIMITED

CIN :- U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise

Audited Standalone Statement of Cash flow for the year ended 31st March, 2025

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	406.57	25.69
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	32.24	4.33
Bad Debts & Balances written off/written back	(55.89)	(12.59)
Preliminary expenses written off	-	-
Re-measurement (gains) / loss on defined benefit plans	12.50	10.30
Provision for doubtful debts	0.07	-
Provision for obsolete inventories	16.62	-
Loss(gain) on account of foreign exchange fluctuations	-	-
Other non-cash transactions(specify nature)	-	-
Non operating transactions		
Interest on borrowing	99.74	63.80
Loss/(profit) on the sale of property, plant & equipments & intangible assets	-	-
Loss/(profit) on the sale of investments	-	-
Interest income	(27.67)	-
Dividend income	-	-
Other non-operating transactions(specify nature)	-	-
Operating profit/(loss) before working capital changes	484.19	91.53
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(263.14)	(227.25)
(Increase) / Decrease in trade receivables	(763.85)	846.49
(Increase) / Decrease in other current assets	(484.51)	(986.99)
(Decrease) / Increase in trade payables	166.33	(102.29)
(Decrease) / Increase in other current liabilities	(41.97)	(22.23)
Net cash (used in) / generated from operating activities	(905.31)	(400.74)
Income taxes refund / (paid), net	-113.8	(3.97)
Net cash flow from operating activities(A)	(1,019.11)	(404.71)
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(22.44)	(18.45)
Sale/(Purchase) of non current & current investments	-	-
Interest income	27.67	-
Dividend income	-	-
Other income	-	-
Net cash flow from investing activities(B)	5.23	(18.45)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	-	-
Proceeds from/(Payment of) long term & short term borrowings	812.73	815.17
Finance cost paid (including processing fees)	(99.74)	(63.80)
Dividend paid	-	(48.45)
Net cash flow from financing activities(C)	712.99	702.92
Net increase/decrease in cash or cash equivalents(A+B+C)	(300.89)	279.76
Cash and cash equivalents at the beginning of the period	316.55	36.79
Cash and cash equivalents at the end of the period	15.66	316.55

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMMOKNN3748

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors

CHANDAN PHARMACY LIMITED

Amar Singh

Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 1 : Corporate information

Chandan Pharmacy Limited, incorporated on 14th August 2017 a division of the Chandan Group, Chandan Pharmacy Limited has quickly established itself in the pharmaceutical sector. With a strong network of medical stores across multiple locations in Uttar Pradesh and operations in three states, the company is committed to providing high-quality healthcare products. Chandan Pharmacy emphasizes accessibility and customer satisfaction, ensuring essential medications and services are available to diverse communities.



Note No. :- 2 : Summary of Significant accounting policies

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

The standalone financial statements were approved by the Board of Directors and authorised for issue on May 27, 2025.

b) Use of Estimates

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

c) Functional and presentation currency

These standalone financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

d) Current and non-current classification:

The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it expects to realise the asset within twelve months after the reporting period;
- it holds the asset primarily for the purpose of trading; or
- the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non current.

A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
- the liability is due to be settled within twelve months from the reporting period;
- it is held primarily for the purposes of being trading;
- it does not hold an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.



e) Significant accounting policies

i.) Revenue recognition

Revenue from the **sale of goods** is recognized when ownership, along with all significant risks and rewards, has been transferred to the buyer, and when there is no significant uncertainty regarding the amount of consideration to be received from the sale.

Revenue from the **sale of services** is recognized using the **completed service contract method**, provided there is no significant uncertainty regarding the amount of consideration to be received for rendering the service.

Sales are accounted for net of amounts recovered towards gst and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognised when no significant uncertainty as to measurability or collectability exists. These revenues are recognised on the following bases:

Interest: On a time proportion basis taking into account the amount outstanding and the rate applicable.

Dividends: When the owner's right to receive payment is established.

ii.) Inventories

Inventories comprise of diagnostic kits ,reagents, laboratory chemicals and consumables, these are measured at lower of cost and net realisable value. The cost of inventories is based on the **weighted average cost formula** and includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-item basis.

iii.) Property, plant & equipments

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefit associated with the item will flow to the Company and the cost of the item can be measured reliably. Items of property, plant and equipment (including capital-work-in progress) are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Freehold land is carried at historical cost less any accumulated impairment losses.

Cost of an item of property, plant and equipment comprises its purchase price, including non refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the items to its working conditions for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of asset.

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iv.) Intangible assets

Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.



v.) Depreciation & Amortisation

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values over their useful lives.

The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight line Method (SLM) as per useful life specified in schedule II of the Companies Act, 2013.

Amortisation is calculated to write off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight line method (SLM) and is included in depreciation and amortisation expense in statement of profit and loss.

Depreciation and amortisation on additions and deletions are restricted to the period of use.

Residual value is considered to be 5% on all the assets.

Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%.

Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

vi.) Employee benefits

Short-term employee benefits

Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A short term liability is recognised if the Company has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount that it contributes to a separate legal entity. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. Obligations for contributions to defined contribution plans are expensed as an employee benefits expense in statement of profit and loss in the period in which the related services are rendered by employees.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan namely gratuity for all its employees. Liability for defined benefit plan is provided on the basis of valuations, as at the balance sheet date, carried out by an independent actuary. The actuarial valuation method used by independent actuary for measuring the liability is the Projected Unit Credit Method. Actuarial gains and losses due to changes in actuarial assumptions and are recognised immediately in the profit and loss account as income or expense. Current and non current liabilities are recognised on the basis of actuarial report.

Termination benefits

Termination benefits are recognised as an expense as and when incurred.

vii.) Lease

Lease contracts entered by the company majorly pertains for buildings taken on operating lease to conduct its business in the ordinary course. Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the statement of profit and loss on a straight line basis over the lease term. Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor. Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

viii.) Impairment of assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the statement of profit and loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use. At each reporting date, the Company reviews the carrying amount of assets, to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.



ix.) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value . Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

x.) Income-tax

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of current tax and deferred tax at the applicable enacted or substantively enacted rates. Current tax represents the amount of income tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

xi.) Provision, contingent liabilities and contingent assets

A **provision** is recognised when the company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on Management's estimate for the amount required to settle the obligation at the balance sheet date.

Contingent liability is a possible obligation arising from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are neither recognised nor disclosed in the financial statements, since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

xii.) Earnings per share

Basic Earnings per share

Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted Earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

xiii.) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.



xiv.) Cash and cash equivalents

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities less than three months which are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

xv.) Dividend

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period, when the distribution is authorised and the distribution is no longer at the discretion of the company on or before the end of the reporting period.

xvi.) Related parties transactions

The company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

xvii.) Foreign Currency Transactions

Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year. Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the closing exchange rates on that date and the resultant exchange differences are recognized in the statement of profit and loss. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined

xviii.) Borrowing Costs

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised as part of such assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

xix.) Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 3 : Share capital

a. Information on authorised, issued, subscribed and paid-up shares

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Authorised		
Equity shares with voting rights	490.00	490.00
(Current year : 4900000 equity shares of Rs.10/- each)		
(Previous year : 4900000 equity shares of Rs.10/- each)		
Total...	490.00	490.00
Issued		
Equity shares with voting rights	32.30	32.30
(Current year : 322996 equity shares of Rs.10/- each)		
(Previous year : 322996 equity shares of Rs.10/- each)		
Total...	32.30	32.30
Subscribed and fully paid		
Equity shares with voting rights	32.30	32.30
(Current year : 322996 equity shares of Rs.10/- each)		
(Previous year : 322996 equity shares of Rs.10/- each)		
Total...	32.30	32.30



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492
Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the year ended 31st March, 2025

a. The reconciliation of shares.

Particulars	Figures as at the end of 31st March, 2025			Figures as at the end of 31st March, 2024		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
Equity shares with voting rights, subscribed and fully paid						
Shares outstanding at the beginning of the year	322,996.00	10.00	3,229,960.00	322,996.00	10.00	3,229,960.00
Add: Fresh shares issued during the year	-	-	-	-	-	-
Add: Bonus shares issued during the year	-	-	-	-	-	-
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	322,996.00	10.00	3,229,960.00	322,996.00	10.00	3,229,960.00

b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital

Equity shares with voting rights, subscribed and fully paid	
As to dividend:	The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by them.
As to repayment of capital:	In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.
As to voting:	The company has only one class of shares referred to as equity shares having a par value of Rs. 10/-. Each holder of the equity share is entitled to one vote per share.



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the year ended 31st March, 2025

c. Details of shareholders holding more than 5% shares of the Company

Name of shareholder	Figures as at the end of 31st March, 2025			Figures as at the end of 31st March, 2024		
	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)
Equity shares with voting rights, subscribed and fully paid						
Name of shareholder						
-Chandan Healthcare Ltd(Shares)	172,992.00	10	53.56%	172,992.00	10	53.56%
-Chandan Hospital Limited(Shares)	149,944.00	10	46.42%	149,944.00	10	46.42%
Total...	322,936.00		99.98%	322,936.00		99.98%

*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.

d. Disclosure of shareholding of promoters:

As at 31st March, 2025

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-AmarAnita Holdings(India) Private Limited	-	-	-	-	0.00%	0.00%
-Amar Singh	10	-	-	10	0.00%	0.00%
-Anant Singh	10	-	-	10	0.00%	0.00%
-Asmita Singh	10	-	-	10	0.00%	0.00%
-Chandan Healthcare Limited	172,992	-	-	172,992	53.56%	0.00%
-Chandan Hospital Limited	149,944	-	-	149,944	46.42%	0.00%
-Vijay Singh	10	-	-	10	0.00%	0.00%
-Bimla Singh	10	-	-	10	0.00%	0.00%
-Vinay Lamba	10	-	-	10	0.00%	0.00%
-Virendra Singh	-	-	-	-	0.00%	0.00%

As at 31st March, 2024

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-AmarAnita Holdings(India) Private Limited	10,001.00	-	10,001.00	-	0.00%	-100.00%
-Amar Singh	60,000.00	-	59,990.00	10.00	0.00%	-99.98%
-Anant Singh	40,000.00	-	39,990.00	10.00	0.00%	-99.98%
-Asmita Singh	10,000.00	-	9,990.00	10.00	0.00%	-99.90%
-Chandan Healthcare Limited	172,992.00	-	-	172,992.00	53.56%	0.00%
-Chandan Hospital Limited	-	149,944.00	-	149,944.00	46.42%	100.00%
-Vijay Singh	5,001.00	-	4,991.00	10.00	0.00%	-99.80%
-Bimla Singh	10.00	-	-	10.00	0.00%	0.00%
-Vinay Lamba	20,001.00	-	19,991.00	10.00	0.00%	-99.95%
-Virendra Singh	5,001.00	-	5,001.00	-	0.00%	-100.00%

*Individuals designated or to be designated by the company as promoters in its annual return.



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 4 : Reserves and surplus

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Surplus/Retained earning		
Opening balance Reserves & Surplus	482	514
Less :- Dividend on equity shares	-	(48)
Add :- Profit/(Loss) for the period	290	16
Total B	772	482
Closing balance (A+B)	772	482



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 5 : Long term provisions

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Provision for gratuity	30.69	22.09
Others(specifying the nature)	-	-
Total...	30.69	22.09

a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:

The company has classified the various benefits provided to employee's as under:-

I. Defined contribution plans

a. Employee's provident fund.

b. Employee's state insurance.

During the year, the company has recognised the following amounts in the profit and loss account:

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Employers' contribution to provident fund*	10.52	3.90
Employers' contribution to employee's state insurance*	4.62	7.71
PF Administration Charges	0.44	0.32
PF EDLI Charges	0.44	0.32
Employer Contribution (PF) (Supplementary)	-	0.10
Total...	16.01	12.36

* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)

II. Defined benefit plans

Gratuity disclosures as per accounting standard-15

(i) Table Showing Changes in Present Value of Obligations

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Present value of the obligation at the beginning of the period	22.70	12.86
Interest cost	1.65	0.96
Current service cost	9.31	7.54
Past Service Cost	-	-
Benefits paid (if any)	(0.60)	(0.45)
Actuarial (gain)/loss	1.55	1.79
Present value of the obligation at the end of the period	34.61	22.70

(ii) Key results (The amount to be recognized in the Balance Sheet):

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Present value of the obligation at the end of the period	34.61	22.70
Fair value of plan assets at end of period	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	34.61	22.70
Funded Status - Surplus/ (Deficit)	(34.61)	(22.70)

(iii) Expense recognized in the statement of Profit and Loss:

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Interest cost	1.65	0.96
Current service cost	9.31	7.54
Past Service Cost	-	-
Expected return on plan asset	-	-
Net actuarial (gain)/loss recognized in the period	1.55	1.79
Expenses to be recognized in P&L #	12.50	10.30

Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)

(iv) Current & Non Current Liability :

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Current Liability (Short Term)^	3.92	0.61
Non Current Liability (Long Term)	30.69	22.09
Total Liability	34.61	22.70

^ Included in Provision for gratuity (Refer Note No. 12 Short term provisions)

(v) Reconciliation of liability in balance sheet

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Opening gross defined benefit liability/ (asset)	22.70	12.86
Expenses to be recognized in P&L	12.50	10.30
Benefits paid (if any)	(0.60)	(0.45)
Closing gross defined benefit liability/ (asset)	34.61	22.70

(vi) Actuarial assumptions provided by the company and employed for the calculations are tabulated:

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Discount rate	7.00 % per annum	7.25 % per annum
Salary Growth Rate	10.00 % per annum	10.00 % per annum
Mortality	IALM 2012-14	IALM 2012-14
Expected rate of return	0	0
Attrition / Withdrawal Rate (per Annum)	20.00% p.a	20.00% p.a



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 6 : Short-term borrowings

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Secured		
Loans repayable on demand		
- From banks-Cash credit(CC)	796.01	683.27
Loans and advances from related parties	699.99	-
	1,496.00	683.27

Particulars	Figures as at the end of 31st March, 2025		Figures as at the end of 31st March, 2024	
	Amount	Nature of security and other terms	Amount	Nature of security and other terms
Secured				
Loans repayable on demand				
- From banks-Overdraft(OD)				
Icici Bank Limited 059105002282	417.22	Sanctioned against FDs with ICIC Bank	-	Sanctioned against FDs with ICIC Bank
- From banks-Cash credit(CC)				
State Bank of India(Cc A/c 41621415835)	-	Hypothecation of stock and book debt	683.27	Hypothecation of stock and book debt
HDFC Bank Ltd 50200100832734	378.78	Hypothecation of stock and book debt	-	Hypothecation of stock and book debt
		Unsecure loan, repayable on demand, From Directors and relative.		Unsecure loan, repayable on demand, From Directors and relative.
Loans and advances from related parties SSTB	699.99		-	



Note No. :- 7 : Trade payables

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	346.32	481.07
- Total outstanding dues of other than micro enterprises and small enterprises	1,157.19	856.11
	1,503.51	1,337.18

a. Trade payables ageing schedule

As at 31st March, 2025

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	346.32	-	-	-	-	346.32
--Others	-	-	1,157.19	-	-	-	1,157.19
Total...	-	346.32	1,157.19	-	-	-	1,503.51

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	481.07	-	-	-	-	481.07
--Others	-	-	856.11	-	-	-	856.11
Total...	-	481.07	856.11	-	-	-	1,337.18

b. Disclosure as per MSMED Act, 2006

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Payable		
Principle overdue as per MSMED Act, 2006.	-	-
Principle not due as per MSMED Act, 2006.	346.32	481.07
Interest payable under section 16 of MSMED Act, 2006	-	-
- On principle paid beyond due date as per MSMED Act, 2006	-	-
- On principle payable beyond due date as per MSMED Act, 2006	-	-
- Carried forward from the last year	-	-
Other interest	-	-
Total...	346.32	481.07
Paid		
Principle paid beyond the due date as per MSMED Act, 2006	-	-
Interest paid under section 16 of MSMED Act, 2006	-	-
Total...	-	-



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 8 : Other current liabilities

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
TDS payable	2.35	10.07
GST payable	19.71	51.49
Salary, Bonus, Gratuity, Reimbursements etc. payable to staff	47.23	54.31
Contribution towards PF payable	2.04	1.89
Contribution towards ESI payable	0.46	0.48
Income tax payable OCL	17.80	12.73
Total...	89.59	130.97



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 9 : Short term provisions

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Provision for employee benefits		
Provision for gratuity	3.92	0.61
	3.92	0.61



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year

Note No. :- 10 : Property, plant & equipments & intangible assets

Description	Gross block			Accumulated depreciation			Net block	
	Figures as at the beginning of 1st April, 2024	Additions during the year	Disposals during the year	Figures as at the end of 31st March, 2025	Figures as at the beginning of April, 2024	For the year	Figures as at the beginning of April, 2024	Figures as at the end of 31st March, 2025
Tangible Assets								
Property, plant and equipment								
Computers	4.65	3.02	-	7.67	4.36	1.39	0.29	1.92
Electric Installation	4.10	1.73	-	5.83	0.19	0.89	3.91	4.75
Office Interior & Renovation	19.61	7.94	0.13	27.42	2.16	10.80	17.44	14.46
Plant and equipment	0.48	0.71	-	1.19	0.03	0.22	0.46	0.94
Furniture and fixtures	21.66	5.49	-	27.16	4.14	12.27	17.53	10.76
Vehicles	5.94	-	-	5.94	0.24	1.12	5.70	4.58
Office equipment	10.30	3.69	-	13.98	3.77	5.57	6.53	4.64
Total...	66.73	22.57	0.13	89.17	14.88	32.24	51.85	42.05
Previous Year...	48.28	33.62	15.17	66.73	10.55	4.33	37.73	51.85



Note No. :- 11 : Non-current investments

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Investments in equity instruments	114.75	114.75
Total...	114.75	114.75

a. Disclosure on investment in equity instrument

As at 31st March, 2025

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Partly paid	1.59%	0.43	270	114.75	Valuers Value	Unquoted
Total...					0.43		114.75		

As at 31st March, 2024

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Partly paid	1.59%	0.43	270	114.75	Valuers Value	Unquoted
Total...							114.75		



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 12 : Deferred tax assets(Net)

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Deferred tax assets(Net)	18.04	3.77
Total...	18.04	3.77

a. Disclosures regarding the components of net deferred tax liabilities

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Provision for gratuity	8.71	-
Provision for doubtful debts	0.02	-
Provision for obsolete inventories	4.18	-
W.D.V of property, plant & equipments & intangible assets	5.13	3.77
Total...	18.04	3.77



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 13 : Long -term loans and advances

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Unsecured, considered good Income tax refund due	0.11	0.11
Total...	0.11	0.11



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492
Lucknow, Uttar Pradesh, India-226021.
stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 14 : Other non-current assets

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Secured, considered good		
Security Deposits	31.19	14.09
Banks deposits with more than twelve months maturity	49.69	26.07
Total...	80.88	40.16



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 15 : Inventories

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Stock-in-trade	1,441.70	1,178.56
Less: Provision for stock obsolescence	(16.62)	-
Total...	1,425.08	1,178.56



Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 16 : Trade receivables

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Unsecured, considered good		
Trade receivables	1,495.07	675.34
Less: Provision for bad and doubtful trade receivables	(0.07)	-
Total...	1,495.00	675.34

a. Trade receivable ageing schedule
As at 31st March, 2025

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	4.58	1,490.49	-	-	-	-	1,495.07
Less: Provision for bad and doubtful trade receivables	-	-	(0.07)	-	-	-	-	(0.07)
Total...	-	4.58	1,490.42	-	-	-	-	1,495.00

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	0.85	674.49	-	-	-	-	675.34
Less: Provision for bad and doubtful trade receivables	-	-	-	-	-	-	-	-
Total...	-	0.85	674.49	-	-	-	-	675.34



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492
Lucknow, Uttar Pradesh, India-226021.
stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 17 : Cash and bank balances

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Cash and cash equivalents		
Balances with banks	4.20	306.40
Cash on hand	11.46	10.15
Total...	15.66	316.55



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 18 : Short-term loans and advances

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Secured, considered good		
Advance to supplier	1.96	4.17
Advance to employees	10.89	8.64
Unsecured, considered good		
Loans and advances to related parties	155.47	245.07
Advance to supplier	-	0.62
Income tax refund due	28.58	-
Total...	196.90	258.50



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 19 : Other current assets

Particulars	Figures as at the end of 31st March, 2025	Figures as at the end of 31st March, 2024
Secured		
Input tax credit(ITC)-GST	13.32	48.53
Prepaid expenses	1.68	-
Bank deposits with more than three months maturity	524.65	-
Total...	539.65	48.53



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 20 : Revenue from operations

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Sale of products	10,124.83	7,611.60
Less: Excise duty	-	-
Total...	10,124.83	7,611.60



CHANDAN PHARMACY LIMITED

U4721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 21 : Other income

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
<u>On current investments</u>		
Interest on fixed deposits	27.67	-
Bad Debts Recovered & Reversal of Payable Write-Off(Net)	55.89	12.59
Other non-operating income	4.14	0.77
Total...	87.70	13.36



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 22 : Cost of material consumed

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Raw materials	-	-
Stores, spares and consumables	16.73	16.07
Total...	16.73	16.07

Consumption disclosed in Note is on the basis of derived figures rather than actual records of issue.



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 23 : Purchase of stock-in-trade

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Purchase of stores, spares and consumables	9,067.65	6,980.79
Total...	9,067.65	6,980.79



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 24 : Change in inventories of finished goods, work-in-progress and stock-in-trade.

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Opening stock: Stock-in-trade	1,178.56	951.31
Closing stock: Stock-in-trade	1,441.70	1,178.56
Total...	(263.14)	(227.25)



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 25 : Employee benefits expense.

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Salaries and wages	519.00	427.20
Contribution to provident and other funds	16.01	12.36
Provision for gratuity	12.50	10.30
Staff welfare expense	0.03	-
Total...	547.54	449.86



CHANDAN PHARMACY LIMITED
U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 26 : Finance costs

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Interest expense on borrowings	87.53	59.08
Other borrowing costs		
Loan processing charges	4.73	1.83
Bank charges	7.49	2.89
	99.75	63.80



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025**Note No. :- 27 : Other expenses**

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Repair & maintenance- Plant & equipments	8.74	15.18
Repair & maintenance-Building	4.28	23.85
Repair & maintenance- Other	15.31	11.67
Payment to auditors	7.00	3.50
Rent	127.83	105.26
Electricity expenses	7.12	4.03
Travelling and conveyance	21.16	14.75
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	32.93	20.85
Commission expenses	-	0.17
Advertisement, publicity, marketing & business promotion expenses	48.86	97.43
Provision for doubtful debts	0.07	-
Provision for obsolete inventories	16.62	-
Communication expenses(Telephone & internet expenses)	6.82	6.80
Insurance	0.90	2.09
Postage & courier charges	0.01	-
Discount to customers	4.76	2.43
Printing and Stationary Expenses	0.01	-
Other miscellaneous expenses	2.77	3.66
	305.19	311.67

a. Payment to the auditor

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
For statutory audit	7.00	3.50
Total...	7.00	3.50

b. Prior period items

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Rent	1.94	0.14
Electricity expenses	0.29	0.14
Communication expenses(Telephone & internet expenses)	0.48	0.48
Maintainence expenses	-	0.02
Rates and taxes	0.00	-
Other miscellaneous expenses	0.00	0.12
Total...	2.71	0.89



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 28 : Earning per share

Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Particulars	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Numerator		
Earning available to equity share holders(EAESH)	290.40	15.79
Denominator		
Weighted average outstanding equity share capital	3.23	3.23
Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)	89.91	4.89



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.
(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025


Note No. :- 29 : Disclosure regarding Transactions with Related Parties in terms of Accounting Standard - 18

A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise	Name of the related party	Nature of the relationship	Nature of the relationship
Chandan Healthcare Limited- PAN: AACCC1996N Chandan Diagnostic Limited- PAN: AABCC9315J Chandan Hospital Limited - PAN: AABCC9314K Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L Chandan Institute Of Medical Sciences Limited - PAN: AAJCC1470E Cendana Pharmaceuticals Private Limited - PAN: AAKCC1991P Amaranita Holdings (I) Private Limited - PAN: AAHCA1540R Chandan Singh Foundation - PAN: AAATC2479F Healthrely Private Limited- PAN: AAGCH9438N* Chandan Cancer Institute Limited- PAN: AALCC9159N* Chandan Super Speciality Hospital Limited- PAN: AALCC1234A*	Holding Company Common director Common director Common director Holding 1.59% of share capital Common director Common director Common director and trustee Common director Common director Common director	Holding Company Common director Common director Holding 1.59% of share capital Common director Common director Common director and trustee - - -	
B. Associates and joint ventures of the reporting enterprise including investing party and venturer of said associates and joint ventures Dr Anar Singh - PAN: AGQPS5396H - DIN: 01096328 Asmita Singh - PAN: AWSPS3853M - DIN: 01098055 Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153 Aasti Singh - PAN: FRPPS0695A - DIN: 06973933 Anant Singh - PAN: AWSPS3852L - DIN: 00969364 Rajeev Nain - PAN: AIVPN6380K Mohammad Mohsin Rizvi - PAN: AQXPR3626G Anita Singh - PAN: ARVPS1208G Vishal Lamba - PAN: ABUPL4208N Ajai Singh - PAN: AHNPS7885B Nisha Lamba - PAN: AATPL6545J Pragya Singh - PAN: DJVPS5075J Vikash Lamba - PAN: ACLPL2389Q	Director of company Director of company Director of company Director of company Director of company Relative of director Relative of director Relative of director Relative of director Relative of director Relative of director Relative of director	Director of company Director of company Director of company Director of company Director of company Relative of director Relative of director Relative of director Relative of director Relative of director Relative of director Relative of director	



a. Details of transactions with related parties and amounts receivable/(payable) as at the beginning and end of the year:

	Nature of Transaction	Figures for the year ended 31st March, 2025	Figures for the year ended 31st March, 2024
Aasti Singh	Opening Balance Payable/(Receivable)	-	-
Dr Amar Singh	Closing Balance Payable/(Receivable)	-	-
	Opening Balance Payable/(Receivable)	-	-
	Dividend for the Year	(25.00)	9.00
	Payment	-	(9.00)
	Receipt	12.50	-
	Reimbursement	12.50	-
Anant Singh	Closing Balance Payable/(Receivable)	-	-
	Opening Balance Payable/(Receivable)	4.90	3.40
	Salary	57.00	54.00
	Dividend for the Year	-	6.00
	Reimbursement	1.70	1.98
	Payment	(59.91)	(60.49)
Asmita Singh	Closing Balance Payable/(Receivable)	3.69	4.90
	Opening Balance Payable/(Receivable)	(5.00)	-
	Dividend for the Year	-	1.50
	Reimbursement	5.00	-
	Payment	-	(6.50)
Anita Singh	Closing Balance Payable/(Receivable)	-	(5.00)
	Opening Balance Payable/(Receivable)	-	-
	Salary	35.00	-
	Payment	(34.82)	6.00
	Reimbursement	(0.18)	(6.00)
Vinay Lamba	Closing Balance Payable/(Receivable)	0.00	-
	Opening Balance Payable/(Receivable)	-	-
	Payment	-	9.90
	Reimbursement	-	(12.90)
	Professional fee	-	-
	Dividend	-	-
	Closing Balance Payable/(Receivable)	-	3.00



Rajeev Nain	Opening Balance Payable(Receivable)	(3.46)	(0.26)
	Professional fee	-	-
	Payment	(0.14)	(3.20)
	Reimbursement	3.60	-
Ajai Singh	Salary	-	-
	Closing Balance Payable(Receivable)	0.00	(3.46)
	Opening Balance Payable(Receivable)	-	-
	Payment	-	-
Nisha Lamba	Closing Balance Payable(Receivable)	-	-
	Opening Balance Payable(Receivable)	-	7.00
	Salary	-	-
	Payment	-	(7.00)
Vikas Lamba	Closing Balance Payable(Receivable)	-	-
	Opening Balance Payable(Receivable)	(0.35)	(0.13)
	Payment	(0.86)	(3.64)
	Reimbursement	1.23	3.41
Vishal Lamba	Closing Balance Payable(Receivable)	-	(0.35)
	Opening Balance Payable(Receivable)	2.04	-
	Reimbursement	13.60	1.80
	Receipt	-	0.15
	Bonus	1.69	3.13
	Salary	37.80	26.95
	Payment	(52.23)	(29.99)
	Closing Balance Payable(Receivable)	2.90	2.04



Mohammad Mohsin Rizvi	Opening Balance Payable(Receivable) Reimbursement Professional Fee Payment Closing Balance Payable(Receivable)	(0.40) - 18.00 (17.60) -	- (0.40) 16.17 (16.17) (0.40)
Chandan Hospital Ltd	Opening Balance Opening Balance share Receipt Advance Account Sales Purchase Rental Share Purchase Payment Closing Balance share Closing Balance Payable(Receivable)	(608.75) 14.99 8,059.66 - (12,851.25) 5,007.16 - - (677.28) 14.99 (1,070.47)	(3.37) - 5,520.41 1.31 (5,892.97) 0.69 - 14.99 (234.82) 14.99 (608.75)
Chandan Institute of Medical Sciences Ltd	Opening Balance Opening Balance share Advance Account Share Purchase Sales of Share Receipt Payment Closing Balance share Closing Balance Payable(Receivable)	(20.13) (300.00) - (114.75) 185.25 205.38 (185.25) (229.50) -	0.14 (300.00) - - - - (20.27) (300) (20.13)
Chandan Healthcare Limited	Opening Balance Payable(Receivable) Opening Balance share Sales Purchase Receipt Dividend Income Rent Payment Advance Account Closing Balance share Closing Balance Payable(Receivable)	(2.92) 17.30 (11.39) 18.44 41.10 - - (41.46) - 17.30 3.78	(565.96) 17.30 (22.79) 16.10 1,091.83 25.95 (0.56) (548.86) 1.38 17.30 (2.92)



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 30 : Analytical ratios

Particulars	Figures for the year ended 31st March, 2025		Figures for the year ended 31st March, 2024		% Variance	Reason for more than 25% variance
Current Ratio						
Total current assets	3,672.29	1.19	2,477.48	1.15	3.13%	NA
Total current liabilities	3,093.02		2,152.03			
Debt-to- Equity Ratio						
Total liabilities	1,496.00	1.86	683.27	1.33	39.90%	As a result of the substantial increase in the short term debt.
Total shareholder's equity	804.41		514.00			
Debt service coverage ratio						
EBIT	494.10	0.31	84.77	0.11	173.25%	As a result of the exceptional growth due to significant increase in net profit.
Current debt obligation	1,583.53		742.35			
Return on Equity (%)						
PAT	290.40	44.05%	15.79	2.98%	1379.56%	As a result of the substantial increase in profitability for the current year.
Average shareholder's equity	659.21		530.32			
Inventory turnover ratio (in days)						
365* Average inventory	475,164	46.93	388,701	51.07	-8.10%	NA
Sales	10,125		7,612			
Trade receivables turnover ratio (in days)						
365* Average account receivables	396,087	31.99	233,691	33.02	-3.14%	NA
Net credit sales	12,383		7,076			
Trade payables turnover ratio (in days)						
365* Average trade payable	518,426	49.10	604,829	68.22	-28.03%	Trade payables have decreased despite an increase in credit purchase
Net credit purchase	10,559		8,865			
Net capital turnover ratio						
Sales	10,125	22.38	7,612	21.01	6.55%	More efficient utilization of working capital to generate revenue.
Average working capital	452.36		362.34			
Net profit ratio (%)						
PAT	290.40	2.87%	15.79	0.21%	1282.62%	As a result of the substantial increase in profitability for the current year.
Sales	10,125		7,611.60			
Return on Capital Employed (%)						
EBIT	494	28.25%	85	5.99%	371.99%	As a result of the substantial improvement in efficiency of capital employed, indicating much better returns from invested funds.
Average (Shareholder's equity + Current & Non current borrowings)	1,748.84		1,416.17			



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 31 : Contingent liabilities and commitments

Particulars	Figures for the year ended 31st March, 2025		Figures for the year ended 31st March, 2024	
	No of cases	Amount	No of cases	Amount
Claims against the company not acknowledged as debts				
1) District consumer disputes redressal forum	-	-	-	-
2) State consumer disputes redressal commission	-	-	-	-
3) Labour court	-	-	-	-
4) District and session court	3.00	20.84	3.00	18.72
Direct tax matters	-	-	-	-
Guarantees	-	-	-	-
Total...	3.00	20.84	3.00	18.72



CHANDAN PHARMACY LIMITED

U47721UP2017PLC193492

Registered address :- Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow, Uttar Pradesh, India-226021.

(All amounts are in ₹ nearest Lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2025

Note No. :- 33 : Other statutory information

In the opinion of the board of directors, the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

Balances with trade receivables / trade payables and loans & advances are subject to confirmation.

Previous year's figures have been regrouped /rearranged wherever necessary to make them comparable with current year's figures.

The company does not have any benami property, where any proceeding has been initiated or pending against the company for holding any benami property.

The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the financial year.

The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

The company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

The company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

The company does not have any transaction to report that is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

The company does not have any immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.

The company confirms that the quarterly returns or statements of current assets, filed with banks or financial institutions in relation to borrowings secured by current assets, are in agreement with the books of accounts.

